Bacterial-derived BLIS for treatment of acne
View Patent ↗This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bactericide or bacteriostat for acne-causing bacteria, namely P. acnes.
1. A method of treating an acne in a subject, the method comprising: administering to said subject, an effective amount of a bacteriocin-like inhibitory substance (BLIS) isolated from Streptococcus salivarius , thereby treating said acne in said subject.
2. The method of claim 1 , wherein the BLIS is SAL A2, SAL B, or a combination thereof.
3. A method of treating an acne in a subject, the method comprising: administering to said subject a composition comprising an effective amount of a bacteriocin-like inhibitory substance (BLIS) isolated from Streptococcus salivarius , wherein the composition further comprises BLIS derived from S. aureus, P. acnes, B. melaninogenicus , or a combination thereof.
4. The method of claim 1 , further comprising coadministering to said subject an additional agent, wherein the agent is isotrenitoin, Benzoyl peroxide, topical retinoid, spironolactone, an oral contraceptive or a combination thereof.
5. The method of claim 1 , wherein said acne is caused by a bacteria resistant to erythromycin, tetracycline, doxycycline, minocycline, oxytetracycline clindamycin, or a combination thereof.
6. A method of treating an acne in a subject, the method comprising administering to said subject an effective amount of a pharmaceutical preparation comprising a bacteriocin-like inhibitory substance (BLIS) from Streptococcus salivarius , whereby said BLIS is bacteriocidal or bacteriostatic for bacteria causing said acne thereby treating said acne in said subject.
7. The method according to claim 6 , wherein said administering comprises orally administering to said subject a liquid or solid formulation containing said pharmaceutical preparation.
8. The method according to claim 6 , wherein said administering comprises topically administering to said subject a formulation containing said pharmaceutical preparation.
9. The method according to claim 6 , wherein said administering comprises administering to said subject a formulation containing said pharmaceutical preparation, wherein said formulation is a food formulation.
10. The method of claim 9 , wherein said food formulation is a yoghurt culture.
11. The method according to claim 6 , wherein said administering comprises administering to said subject a formulation containing said pharmaceutical preparation, wherein said formulation is a probiotic capsule.
12. The method of claim 6 , further comprising a pharmaceutically acceptable carrier, excipient, flow agent, processing aid, a diluent or a combination thereof.
13. The method of claim 12 , wherein said carrier, excipient, lubricant, flow agent, processing aid, diluent or a combination thereof, is a gum, a starch, a sugar, a cellulosic material, an acrylate, calcium carbonate, magnesium oxide, talc, lactose monohydrate, magnesium stearate, colloidal silicone dioxide or mixtures thereof.
14. The method of claim 6 , wherein said pharmaceutical preparation is in the form of a pellet, a tablet, a capsule, a solution, a suspension, a dispersion, an emulsion, an elixir, a gel, an ointment, a cream, a foam or a suppository.
15. The method of claim 6 , wherein said pharmaceutical preparation is a liquid dosage form.
16. The method of claim 6 , wherein said pharmaceutical preparation is a solid dosage form.
17. The method of claim 6 , wherein treating is preventing, reducing incidence of, inhibiting, reducing symptoms or their severity or a combination thereof.
18. A method of suppressing, inhibiting the growth of, or killing a P. acnes bacteria comprising the step of contacting said bacteria with a bacteriocin-like inhibiting substance (BLIS), wherein said BLIS is a bacteriocide or a bacteriostat of P. acnes , and wherein said BLIS is isolated from Streptococcus salivarius.